Patients Underwent Repeat Procedures Research Articles

Concurrent assessment of time-to-isolation and temperature at 30 s as an innovative metric for predicting the persistence of pulmonary vein isolation using second-generation cryoballoons

BackgroundWe attempted to establish correlations between intraoperative variables such as time-to-isolation (TTI) and temperature (T) at the 30-second mark, and the sustained efficacy of pulmonary vein isolation.MethodsOne hundred patients underwent repeat procedures subsequent to their index ablation. Five time intervals were delineated based on TTI metrics of 30, 35, 40, 45, and 60 s during the initial procedure. Subsequently, temperatures of -25 °C, -29 °C, -30 °C, and − 31 °C were determined at 30 nodes during repeat procedures, guided by the findings from the initial intervention. The prevalence of re-established pulmonary vein (PV) potentials was assessed both prior to and post each TTI and temperature assessment at the 30-second node.ResultsThe incidence of reconnected PV potentials demonstrated a noteworthy reduction in the group with TTI < 30 s group than in the TTI ≥ 30. Similarly, there was a notable decrease in the incidence of reconnected PV potentials in the group with T at 30 s of < -31 ℃ than ≥ -31 ℃. The sensitivity, specificity, and positive predictive values (PPVs) for predicting durable pulmonary vein isolation were 13.19%, 94.44%, and 83.72%, respectively, in cases where the TTI was < 30 s and T at 30 s was < -31 ℃.ConclusionIntegrating both TTI30s and T30s could potentially serve as an effective method for predicting the persistence of pulmonary vein isolation using second-generation cryoballoons.

Outcomes of Endovascular Treatment for Salvaging Failed Hemodialysis Arteriovenous Fistula - Role of Balloon Angioplasty as Initial Therapy.

This study aims to evaluate the technical and clinical outcomes of endovascular treatment for failed native hemodialysis fistulas, mainly the role of balloon angioplasty in salvaging thrombosed and stenosed arteriovenous fistulas. This retrospective study was done on 23 patients who had presented with non-functioning dialysis fistulas. The mean age of the patients was 58.7 ± 2.3 years. The cause of failure was thrombosis in 14 cases (61%) and stenosis in 9 cases (39%). All patients initially underwent percutaneous transluminal angioplasty (PTA), followed by thromboaspiration depending on the thrombus load and extent. A total of 27 salvage procedures were performed on 23 patients. Technical success was achieved in 24 procedures (88.8%), and clinical success was 81.5%. Patients were followed up for mean duration of 9.5 months (range: 1-19 months). Eight out of 23 accesses initially revised failed again due to repeat thrombosis, of which four patients underwent repeat procedures. The mean duration to re-intervention was 5.5 ± 1.3 months. The primary patency rates were 79% at 3 months and 60% at 6, 12, and 18 months. The cumulative (secondary) patency rates were 73% at 6 months and 66% at 12 and 18 months. Minor complications were seen in three procedures (11%), which included venous extravasation in two cases and prolonged bleeding from puncture site in one case. Percutaneous balloon angioplasty can be used as first-line procedure in failed hemodialysis fistulas, in both cases of stenosis and/or thrombosis, followed by thromboaspiration if required.

Reasons for repeat urgent cardiac procedures within the same day.

With advances in technology and technique, the expectations are that patients undergoing procedures in the cardiac catheterization laboratory will not need to return for a repeat procedure within the same day. Report why subjects undergoing cardiac procedures return urgently to the catheterization laboratory for a repeat procedure during the same day. We retrospectively reviewed patients who were brought back to the cardiac catheterization laboratory within the same day for a repeat procedure. The reasons for index and repeat procedure were identified. Patients who were transferred from an outside center after an initial procedure at other centers were excluded. Between November 2013 and January 2022, 55,942 catheterization procedures were performed at our institution, of which 140 entries were included in our analysis. Common reasons for the index procedure were diagnostic angiography (35.0%), percutaneous coronary intervention (PCI, 29.2%), and transcatheter aortic valve replacement (15.0%). The most common reason for bringing these patients back to the cardiac catheterization laboratory within the same day was vascular complications (24.2%), followed by repeat PCI (20.7%), need for hemodynamic support (15.0%), heart team discussion and PCI (10%), and pacemaker implantation (10%). Acute limb ischemia was the most commonly identified vascular complication (7.1%), followed by pseudoaneurysm (5%). Our study demonstrates that a very small number of patients underwent repeat procedures within the same day. Special attention should be paid to vascular access and closure and assessment of recurrent chest pain postprocedure, as these are the main reasons for same-day repeat procedures.

Measures to Prevent Infection in Cardiac Implantable Electronic Device Replacements or Upgrades.

Cardiac implantable electronic device (CIED) infections represent one of the most threatening complications associated with device implantation, due to an increase in morbidity and mortality rates, as well as healthcare costs. Besides, it is important to highlight that when compared to the initial implantation of a device, the risks associated with procedures like generator changes, lead and pocket revisions, or device upgrades double. Consequently, to address this issue, various scoring systems, like the PADIT (Prior Procedures, Age, Depressed Renal Function, Immunocompromised Status, Type of Procedure), the RI-AIAC (Ricerca Sulle Infezioni Associate a ImpiAnto o Sostituzione di CIED), and the Shariff score, along with predictive models, have been developed to identify patients at a greater risk of infection. Moreover, several interventions have been assessed to evaluate their role in infection prevention ranging from improving skin preparation and surgical techniques to considering alternative strategies such as the subcutaneous Implantable Cardioverter-Defibrillator (ICD). Methods like antimicrobial prophylaxis, pocket irrigation, chlorhexidine gluconate pocket lavage, capsulectomy, and the use of antibacterial envelopes have been also explored as preventive measures. In this review, we provide a comprehensive assessment of CIED infections in patients undergoing repeat procedures and the strategies designed to reduce the risk of these infections.

Risk of stiff left atrial syndrome following pulse-field-based ablation of atrial fibrillation in patients with pulmonary hypertension at baseline

Abstract Introduction Studies have reported development of stiff LA syndrome, defined as pulmonary hypertension (PH) secondary to reduced LA compliance, in some patients following AF ablation. Purpose We compared the risk of worsening of baseline PH in non-paroxysmal AF (persistent and long-standing persistent AF) patients undergoing repeat procedures, either pulse-field ablation (PFA) or standard radiofrequency ablation (RFA). Methods This multicenter study included 28 non-paroxysmal AF patients with PH, undergoing PFA-based ablation procedure after &amp;gt;1 failed radiofrequency ablations (RFA). A cohort of 28 AF patients with PH that were scheduled for repeat RF ablation were identified. Propensity scores were computed using multivariate logistic model. Twenty-eight patients from the RFA cohort were selected by 1:1 propensity score matching with the PFA group. Right heart catheterization was performed pre- and post-procedure to assess the Pulmonary artery pressure (PAP). PH was defined as resting mean PAP of ≥20 mmHg. The follow-up PAP and change from baseline were compared between PFA and RFA groups, after controlling for baseline PAP in an ANCOVA model. Results Baseline characteristics of PFA (age 62.21 ± 9.3 yrs, male 19 (67.9%), LAD 3.7 ± 0.66 cm) and propensity-matched RF groups (age 62.39 ± 9.3 yrs, male 18 (64.3%), LAD 3.7 ± 0.74 cm) were comparable. The mean pulmonary artery pressure (PAP) assessments at baseline, follow-up and change from baseline are presented in table below. The groups had comparable baseline PAP (p= 0.157). At follow-up, RF group reported 19.81 mm Hg increase in PAP (within-group p &amp;lt;0.001). In PFA group, follow-up PAP showed a decreasing trend (-1.67 mm Hg, within-group p= 0.114). Compared to PFA, the change was significantly higher in RFA (p &amp;lt;0.0001) after controlling for baseline PAP). Conclusion In this propensity-matched population, pulse-field ablation was demonstrated to be a safer option in terms of post-ablation worsening of PAP, compared to the RF ablation in AF patients with pulmonary hypertension at baseline.

Repeat ablation strategy for recurrent persistent atrial fibrillation: A propensity-matched score comparison between "2C3L" and "extensive ablation" approach.

Debates exist in the repeat ablation strategy for patients with recurrence presenting as persistent atrial fibrillation (AF) after initial persistent AF ablation. To compare the outcome between the "2C3L" and "extensive ablation" approach in patients undergoing repeat procedures for recurrent persistent AF. Propensity-score matching was performed in 196 patients with AF recurrence undergoing repeat ablation, and 79 patients treated with "2C3L" strategy were matched to 79 patients treated with "extensive ablation" strategy. The "2C3L" approach included pulmonary vein isolation, mitral isthmus, left atrial roof, and cavotricuspid isthmus ablation, while the "extensive ablation" strategy included extensive ablation of a variety of other targets aiming to terminate the AF. The primary outcome was freedom from any atrial tachyarrhythmia after 24-h ambulatory monitoring follow-up for 12 months. No statistically significant difference was found between the primary outcome between the "2C3L" and the "extensive ablation" group [70.9%vs. 69.6%, p=.862; 95% confidence interval (CI) -12.8 to 15.3], although the "extensive ablation" group had a significantly high proportion of AF termination (19.0% for "2C3L" vs. 41.8% for "extensive ablation" group, p=.002; 95% CI 8.5-35.9). And AF termination was not related to the primary outcome in multifactorial regression. At 40±22 months after the repeat procedure, the primary outcome was also comparable (57.0 % for "2C3L" vs. 48.1% for "extensive ablation" group, p=.265; 95% CI -6.6 to 23.7). The outcome between the "2C3L" and "extensive ablation" approaches was comparable in patients undergoing repeat procedures for recurrent persistent AF.

Embolization of parastomal and small bowel ectopic varices utilizing a transhepatic antegrade approach: A case series.

BackgroundThe ideal approach to managing parastomal and small bowel ectopic varices (EVs) is yet to be established.PurposeTo evaluate outcomes following percutaneous antegrade transhepatic venous obliteration (PATVO) in patients presenting with bleeding from parastomal or small bowel EVs.Material and MethodsA case series of 12 patients presenting with active or recurrent bleeding from parastomal or small bowel EVs who underwent 17 PATVO interventions at our tertiary care institution was performed. Data extraction from electronic medical records included baseline characteristics and procedural details. Endpoints included technical success, early clinical success, and re-bleeding.ResultsTechnical success was 100% (n = 17), and early clinical success was 82.3% (n = 14). No patient experienced any intra- or post-operative complications. Rebleed rates after initial PATVO in patients who achieved early clinical success was as follows: 3-month, 0% (n = 0); 6-month, 20% (n = 2); 12-month, 20% (n = 2). Rebleed rates after all PATVO procedures (including patients undergoing repeat procedures) that achieved early clinical success were as follows: 3-month, 0% (n = 0); 6-month, 14% (n = 2; 12-month, 14% (n = 2). All patients with re-bleeding required reintervention with either PATVO, transjugular intrahepatic portosystemic shunt (TIPS) or both.ConclusionPATVO can be safely performed to treat bleeding from parastomal and small bowel EVs. In patients who present with recurrent bleeding despite PATVO, TIPS with/without embolization of bleeding varices remains a valid option as described by the literature.

Linear lesions for treating the recurrence of persistent atrial tachyarrhythmia after cryoballoon ablation of atrial fibrillation

There is no consensus on the most effective radiofrequency ablation strategy for the initial or repeated treatment of persistent atrial tachyarrhythmia (ATa). To describe success and complication rates after the creation of left atrial (LA) linear lesions for recurrent persistent ATa following an index cryoballoon pulmonary vein isolation (PVI), and to identify predictors of ATa recurrence. During March 2013 to March 2020, we prospectively included all consecutive patients undergoing repeat procedures for the treatment of persistent ATa. Radiofrequency ablation consisting of the creation of linear lesions: a roofline, a mitral isthmus and/or septal line, and a cavotricuspid isthmus line. All patients were prospectively followed up for ATa recurrence. Overall, 133 patients underwent 170 procedures after initial cryoballoon PVI (n=715). At least one pulmonary vein reconnection was observed in 60 patients (45.1%), all of whom underwent successful re-disconnection. After all the procedures, >90% of patients had a lesion pattern consisting of a roofline, a mitral isthmus and/or septal line, and a cavotricuspid isthmus line. ATa was terminated in 41 patients (35%). There were three cases of tamponade (3/170 procedures, 1.8%). Ninety-two patients (69.2%) were in sinus rhythm after a median (interquartile range) of 36 (21-53) months since the index cryoballoon PVI. Diagnosis-to-ablation time and LA area were predictors of recurrence in multivariable analysis. The creation of linear lesions is a safe and effective treatment strategy for the recurrence of persistent ATa after cryoballoon PVI. Longer diagnosis-to-ablation time and larger LA area were predictive of ATa recurrence.

Repeat procedures for recurrent persistent atrial fibrillation: A propensity-matched score comparison between left atrial linear ablation with radiofrequency and posterior wall isolation with the cryoballoon.

AimsTo evaluate the clinical outcome in patients undergoing repeat procedures for recurrent persistent atrial fibrillation following an index cryoballoon (CB‐A) pulmonary vein isolation ablation on a mid‐term follow‐up of 12 months.MethodsIn this propensity score‐matched comparison, 50 patients undergoing left atrial posterior wall isolation (LAPWI) with the CB‐A were matched to 50 patients treated with additional linear ablation using radiofrequency catheter ablation (RFCA).ResultsMeantime to repeat the procedure was 9.74 ± 4.36 months. At 12 months follow‐up freedom from atrial tachyarrhythmias (ATas) was achieved in 82% of patients in the LAPWI group and in 62% of patients in the linear ablation group (P = .03). Regression analysis demonstrated that relapses during the blanking period and LA dimensions were independent predictors of ATas recurrences following the repeat procedure.ConclusionLAPWI using CB‐A is associated with a significantly higher freedom from atrial arrhythmias when compared with the RFCA mediated left atrial linear lesions on a mid‐term follow‐up of 12 months in patients with persAF undergoing a redo procedure.

Durable pulmonary vein (PV) isolation at repeat atrial fibrillation (AF) ablation procedure: a comparison between 4 ablation technologies

Abstract Background Durable PV isolation is the sought-after endpoint to obtain long term success after AF catheter ablation. Evolution in technology improves efficiency, safety and effectiveness in AF catheter ablation. Purpose To investigate the effectiveness of different catheter technologies in obtaining durable PV isolation in a real-world practice. Methods Retrospective analysis of prospectively collected data of patients undergoing repeat procedures for recurrence of AF or atrial flutter at our institution was performed. Incidence of all PVs being isolated at repeat procedure was recorded and patients 4 groups created based on catheter technology used during index AF ablation procedure (SF: multipored, irrigated catheter; ST: contact force sensor catheter; Cryo: 2nd generation cryobaloon; and STSF: multipored, irrigated, contact force sensing catheter). Results We identified 269 subjects undergoing repeat ablation from May 2014 to September 2019. Mean age was 67±9.7 years, 54.6% were males, 74.4% non-paroxysmal AF at the index procedure. The mean CHA2DS2Vasc score was 2.5±0.26, LA size 4.2±0.6 cm, EF 55.3±10%. The mean time from index to redo procedure was 374±331 days. At repeat procedure all veins were isolated in 24% (6/25) who were initially ablated using SF; 36% (8/22) with Cryo; 44% (47/108) with ST; and 74% (84/114) with STSF catheter. (Figure) Conclusion Patients undergoing index ablation with STSF catheter technology were significantly more likely to have all 4 PVs isolated at repeat procedure compared to previous generation technology. Funding Acknowledgement Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Biosense Webster

Mechanisms of long-term recurrence three years after catheter ablation of atrial fibrillation

Abstract Background AF is a progressive disease, and the mechanism underlying long-term recurrence after AFCA is unclear. Purpose This study explored the potential mechanisms of long-term recurrence (LTR) of atrial fibrillation (AF) 3-years after AF catheter ablation (AFCA). Methods Among 2,209 consecutive patients who underwent AFCA, 1,325 (59±11 years, 72.5% male) who underwent regular rhythm follow-ups for &amp;gt;3-years were enrolled. Among them, 659 patients remained in sinus rhythm (SR), 327 recurred after 3–12 months (short-term recurrence; STR), 235 after 1–3 years (mid-term recurrence; MTR), and 104 after 3-years (long-term recurrence; LTR). Two hundred eighteen recurrent patients underwent repeat procedures: 112, 80, and 26 in the STR, MTR, and LTR groups, respectively. Results The pre-ablation left atrial (LA) dimensions were larger in the STR (p&amp;lt;0.001) and MTR groups (p&amp;lt;0.001), but not in the LTR group compared to the SR group. Low LA voltages were independently associated with an LTR (adjusted HR 0.57 [0.36–0.92], p=0.022). Upon the redo-mapping, the number of reconnected pulmonary veins (PVs) was 2.0 (IQR 0–3), 1.5 (IQR 0–3), and 1.0 (IQR 0–2) in the STR, MTR, and LTR groups, respectively (p=0.030). Post-ablation extra-PV triggers were more commonly found in the LTR than STR or MTR groups (LTR 40.9% to STR 19.2%, p=0.014) during the second procedure. Conclusions The LTR group had a similar baseline LA size and significantly lower LA voltage than the SR group. In the repeat procedures, the LTR group had fewer reconnected PVs, but extra-PV triggers were more common than in the STR and MTR groups. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Ministry of Health and Welfare, Ministry of Science, ICT &amp; Future Planning (MSIP).

Mechanisms of Long-Term Recurrence 3 Years After Catheter Ablation of Atrial Fibrillation.

This study explored the potential mechanisms of long-term recurrence (LTR) of atrial fibrillation (AF) 3 years after AF catheter ablation (AFCA). AF is a progressive disease, and the mechanism underlying long-term recurrence after AFCA is unclear. Among 2,209 consecutive patients who underwent AFCA, 1,325 (age 59 ± 11 years, 72.5% male) who underwent regular rhythm follow-ups for >3 years were enrolled. Among them, 659 patients remained in sinus rhythm (SR), 327 recurred after 3 to 12months (short-term recurrence [STR]), 235 after 1 to 3 years (mid-term recurrence [MTR]), and 104 after 3 years (long-term recurrence [LTR]). Two hundred-eighteen recurrent patients underwent repeat procedures: 112, 80, and 26 in the STR, MTR, and LTR groups, respectively. The pre-ablation left-atrial (LA) dimensions were larger in the STR (p<0.001) and MTR groups (p<0.001) but not in the LTR group compared with the SR group. Low LA voltages were independently associated with an LTR (adjusted hazard ratio [HR]: 0.57 [0.36 to 0.92]; p=0.022). Upon the redo mapping, the number of reconnected pulmonary veins (PVs) was 2.0 (interquartile range [IQR]: 0 to 3), 1.5 (IQR: 0 to 3), and 1.0 (IQR: 0 to 2) in the STR, MTR, and LTR groups, respectively (p=0.030). Post-ablation extra PV triggers were more commonly found in the LTR than STR or MTR groups (LTR 40.9% to STR 19.2%; p=0.014) during the second procedure. The LTR group had a similar baseline LA size and significantly lower LA voltage than the SR group.Inthe repeat procedures, the LTR group had fewer reconnected PVs, but extra PV triggers were more commonthanintheSTR and MTR groups.

Evaluation of left atrial linear ablation using contiguous and optimized radiofrequency lesions: the ALINE study.

Achieving block across linear lesions is challenging. We prospectively evaluated radiofrequency (RF) linear ablation at the roof and mitral isthmus (MI) using point-by-point contiguous and optimized RF lesions. Forty-one consecutive patients with symptomatic persistent AF underwent stepwise contact force (CF)-guided catheter ablation during ongoing AF. A single linear set of RF lesions was delivered at the roof and posterior MI according to the 'Atrial LINEar' (ALINE) criteria, i.e. point-by-point RF delivery (up to 35 W) respecting strict criteria of contiguity (inter-lesion distance ≤ 6 mm) and indirect lesion depth assessment (ablation index ≥550). We assessed the incidence of bidirectional block across both lines only after restoration of sinus rhythm. After a median RF time of 7 min [interquartile range (IQR) 5-9], first-pass block across roof lines was observed in 38 of 41 (93%) patients. Final bidirectional roof block was achieved in 40 of 41 (98%) patients. First-pass block was observed in 8 of 35 (23%) MI lines, after a median RF time of 8 min (IQR 7-12). Additional endo- and epicardial (54% of patients) RF applications resulted in final bidirectional MI block in 28 of 35 (80%) patients. During a median follow-up of 396 (IQR 310-442) days, 12 patients underwent repeat procedures, with conduction recovery in 4 of 12 and 5 of 10 previously blocked roof lines and MI lines, respectively. No complications occurred. Anatomical linear ablation using contiguous and optimized RF lesions results in a high rate of first-pass block at the roof but not at the MI. Due to its complex 3D architecture, the MI frequently requires additional endo- and epicardial RF lesions to be blocked.

Long-term outcome of catheter ablation for left posterior fascicular ventricular tachycardia with the development of left posterior fascicular block and characteristics of repeat procedures

ObjectiveThe present study aimed to retrospectively investigate long-term clinical outcomes of patients undergoing catheter ablation of left posterior fascicular ventricular tachycardia (LPF-VT) with the development of left posterior fascicular block (LPF block) and characteristics of repeat procedures. Methods and resultsA total of 195 patients (mean age 29.76±1.03years, 16.4% females) who underwent catheter ablation for LPF-VT were consecutively enrolled. The earliest ventricular potential with a single fused Purkinje potential (PP) during VT and the PP located in the inferior-apical or mid-apical septum during SR were targeted for linear ablation. The endpoint of the procedure was noninducible VT and development of new-onset LPF block. Follow-up with clinic visits or telephonic interviews, electrocardiogram (ECG), or Holter monitoring was performed after the procedure. With a median follow-up of 85 (18,181) months, 20 patients were censored and 152 of 175 (86.86%) patients had long-term freedom from VT after a single procedure. No statistical difference in the outcome of catheter ablation of LPF-VT was found between inducible and non-inducible groups (P=0.89). Twenty-three patients exhibited recurrent LPF-VT. Seven of 23 patients developed new-onset left upper septal ventricular tachycardia that was successfully ablated. All the patients undergoing repeat procedures had freedom from VT. No procedural complications occurred. ConclusionsAblation of LPF-VT using the development of LPF block as the endpoint is associated with a high procedural success rate. No difference in freedom from LPF-VT was found between inducible and non-inducible patients. New-onset LPF block recovery and non-early PP-QRS interval can be the predictors of LPF-VT repeat procedure.

Pulmonary Vein Isolation Using a Second-Generation Cryoballoon in Patients With Paroxysmal Atrial Fibrillation: One-Year Outcome Using a Single Big-Balloon 3-Minute Freeze Technique.

The second-generation cryoballoon (CB) has been recently introduced into clinical use for pulmonary vein isolation (PVI). Data on the feasibility, long-term outcome, and optimal freeze cycle are still limited. We assessed the 1-year clinical outcome after second-generation CB ablation with single 3-minute freeze techniques, and clinical variables associated with AF recurrence. A total of 108 paroxysmal atrial fibrillation (PAF) patients undergoing cryothermal PVI were enrolled. PVI was performed with one 28-mm CB using single 3-minute freeze techniques without bonus applications. Fourteen-day consecutive monitoring was done after discharge to detect early AF recurrences (ERAFs). Out of 425 PVs, 409 (96.2%) were isolated using exclusively CBs, and 16 required touch-up ablation. Transient phrenic nerve injury, pericardial tamponade, and 50% PV stenosis occurred in 9, 1, and 1 patients, respectively. No PV stenosis >50% was observed in any patients. The total procedure and fluoroscopic times were 82.9±26.4 and 26.2±14.8 minutes, respectively. ERAFs were detected in 51 (47.2%) patients. At 1-year after single and repeat procedures, 71.6% and 84.3% of the patients were free from recurrent AF off antiarrhythmic drugs (AADs), respectively. Eighteen patients underwent repeat procedures (median 6.0 [4.0-9.3] months post procedure), and 68.6% of PVs were still isolated. Cox's proportional models determined that ERAFs were significantly associated with AF recurrence (HR = 7.236; 95%CI = 2.753-19.016; P < 0.0001). AF-freedom off AADs at 1-year after single procedures was 90.8% and 50.3% in patients without and with ERAFs. Second-generation CB ablation using single 3-minute freeze techniques appears feasible in PAF patients. ERAFs were significant factors for predicting clinical outcomes.

Outcomes of Atrial Fibrillation Ablation: The Auckland Experience

Background: This study reports the outcomes of atrial fibrillation (AF) ablations performed at Auckland City Hospital (ACH). Methods: Retrospective analysis of AF ablations performed at ACH between September-2007 and November-2015. 9 patients who had prior AF ablations at other institutions were considered repeat procedures. Results: 268 patients underwent 328 procedures. 79.1% had one procedure, 19.4% had two and 1.5% had three procedures. AF was paroxysmal (PAF) in 64.2% and persistent (PeAF) in 35.8%. At 1 year follow-up after their index procedure, 75% of the PAF group and 67.5% of the PeAF group remained free from AF. 15.7% of patients with PAF and 30.2% with PeAF required a second procedure. After one repeat ablation, 78.6% of the PAF group and 65.6% of the PeAF group were free from AF at 1 year follow-up. 0.6% of patients with PAF and 3.1% of patients with PeAF required a third PVI. 1 year after their second repeat ablation, 66.6% of the PeAF group remained free from AF. Intraoperative complications included 4 pericardial effusions and 2 adverse drug reactions. Post-procedural complications included groin haematoma (15), pseudoaneurysm or arteriovenous fistula (6), transient phrenic nerve palsy (13) and fluid overload (6). Serious adverse events included 1 cardiac tamponade and 1 cardiac arrest due to protamine. 7 patients developed pulmonary vein stenosis, 4 of whom were undergoing repeat ablation. Conclusion: Patients undergoing AF ablation at ACH have a satisfactory rate of success and low rate complications overall. However, significant pulmonary complications have occurred mainly in patients undergoing repeat procedures.

Rates of interventional procedures in patients with tuberous sclerosis complex-related renal angiomyolipoma

Objective:To describe rates of renal artery embolization, partial nephrectomy, and complete nephrectomy in patients with tuberous sclerosis complex (TSC) and renal angiomyolipoma.Methods:Data from the MarketScan® Research Databases were used to select patients with TSC and renal angiomyolipoma during January 1, 2000–March 31,2013 (Commercial database) and January 1, 2000–June 30, 2012 (Medicaid database). Patients had at least 30 days of follow-up and were followed until the earliest of inpatient death, end of enrollment, or end of study. Rates of embolization and nephrectomy were calculated.Results:In total, 218 patients <18 years (mean = 9.7 years) and 378 patients ≥18 years (mean 36.9 years) were selected from the Commercial database. Fifty-nine patients <18 years (mean = 7.2 years) and 117 patients ≥18 years (mean = 37.2 years) were selected from the Medicaid database. Follow-up in the Medicaid cohorts was approximately twice that of the Commercial cohorts. Among patients in the study, 24.2% had at least one interventional procedure: 15.2% had embolization, 5.2% had partial nephrectomy, and 7.6% had complete nephrectomy. Within the Commercial cohort ≥18 years, 18.5% had embolization, 7.7% had partial nephrectomy, and 11.4% had complete nephrectomy. Corresponding percentages in the Medicaid adult cohort were 17.1%, 5.1%, and 4.3%. Repeat embolization procedures occurred in up to 7.7% of Commercial patients and in up to 6.8% of Medicaid patients. Repeat partial nephrectomy occurred in up to 4.5% and 1.7% of Commercial and Medicaid patients, respectively.Conclusions:Approximately 25% of patients with TSC-renal angiomyolipoma experienced embolization or nephrectomy, with some patients undergoing repeat procedures. Study limitations included small sample sizes, the majority of the study period occurred prior to the approval of mammalian target of rapamycin inhibitors for the treatment of TSC-renal AML, and results may not be generalizable to patients with insurance other than commercial or Medicaid.

NMARQ Ablation for Atrial Fibrillation: Results from a Multicenter Study.

nMARQ is a multipolar catheter designed to simultaneously ablate at multiple sites around the pulmonary vein (PV) circumference with a single radiofrequency application. We sought to define the safety and efficacy of atrial fibrillation (AF) ablation with the nMARQ catheter. In a multicenter study, patients with drug-refractory AF were included. Procedural outcomes were documented at 1 year. 374 patients underwent PV isolation using nMARQ (age 60 ± 10 years, 264 male), of whom 263 patients had paroxysmal AF (PAF), while 111 patients had persistent AF. A total of 1,468 of 1,474 veins (99.6%) were isolated with the nMARQ catheter alone. Thirty-five (13%) PAF patients and 30 (27%) persistent AF patients underwent additional ablation at non-PV sites (2.4 ± 1.4 non-PV sites). Procedure time for PV isolation only was 1.9 ± 0.7 hours (fluoroscopy 24 ± 14 minutes). Procedure time for PV isolation and non-PV ablation was 2.4 ± 1.0 hours (fluoroscopy 30 ± 23 minutes). Major adverse events occurred in two patients (0.5%); one esophago-pericardial fistula and a second, mortality due to sepsis of unknown cause. One-year follow-up data were available in 65 (25%) PAF and 20 (18%) persistent AF patients. Forty-two (65%) PAF and 13 (65%) persistent AF patients were free of arrhythmia at 1 year. In patients undergoing repeat procedures (n = 17) the most frequent points of PV reconnection were: anterior RSPV, inferior RIPV, and superior LSPV. AF ablation with nMARQ is associated with short procedure times and high acute success rates. Further research is necessary to more clearly define long-term outcome.

Clinical outcome when left atrial posterior wall box isolation is included as a catheter ablation strategy in patients with persistent atrial fibrillation.

Isolation of the pulmonary veins alone (PVI) is associated with a 50 to 70 % success rate in paroxysmal atrial fibrillation (AF) but is significantly lower for persistent AF. We sought to evaluate patient outcomes in terms of safety and efficacy when posterior left atrial box isolation is included as a catheter ablation strategy in patients with mainly persistent AF. We performed an audit of 100 patients undergoing left atrial (LA) box isolation. Recurrence of arrhythmia was detected by evaluating symptoms and continuous 24 h ECG monitoring at 2, 6 and 12 months post procedure. Seventy-two patients had persistent AF prior to procedure. Average duration of AF was 5.4 ± 5.2 years. All patients underwent circumferential PVI plus linear posterior LA lines to complete box isolation. At a mean follow-up of 12.5 ± 4.2 months, 75 patients were free from atrial fibrillation, 50.6 % of these were taking no antiarrhythmic medication. Twenty-five patients had recurrence of AF, 84 % of whom had previous persistent AF. The average time to recurrence post procedure was 5.9 ± 4.4 months. Thirteen patients underwent repeat procedures for recurrent AF. There were no adverse events relating to the procedure. These results suggest that the strategy of left atrial box isolation is safe and effective, worthy of further evaluation in a multicentre registry.

Percutaneous cryoablation of ovarian cancer metastasis to the liver: initial experience in 13 patients.

To evaluate the feasibility, safety, and effectiveness of percutaneous cryoablation for the treatment of liver metastases from ovarian cancer. A retrospective review was performed on 13 patients with liver metastases from ovarian cancer who underwent percutaneous cryoablation with computed tomography (CT) guidance. The tumor response was assessed by enhanced computed tomography performed before treatment, 1 month after, and every 3 months after treatment. The Functional Assessment of Cancer Therapy-General quality of life (QOL) was used to assess the patients' QOL before, 1 week, 1 month, and 3 months after cryoablation. A total of 27 procedures of cryoablation were performed on these patients, and 5 patients underwent repeat procedures. Complete ablation was achieved for all lesions. Months are counted from the time of cryoablation, and the median duration of follow-up was 15 months (4-22 months). At the 1-month follow-up, the primary technique effectiveness was 100%. At the 3-month follow-up, local tumor progression was observed in 2 (7.14%) of 28 lesions. The 1-year survival from the time of cryoablation was 92.3%. Two patients died after 9 and 14 months, respectively. The QOL symptoms and functioning scales were preserved in patients alive at 3 months after cryoablation. No major complications such as cryoshock, hepatic bleeding, liver abscess, biliary fistula, and renal insufficiency were encountered. Our initial experience showed that cryoablation is a safe and effective ablative therapy, providing a high rate of local tumor control in ovarian cancer liver metastases.